Navigation Links
Oncolytics Biotech Inc. Starts Patient Enrolment in U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
Date:9/8/2008

CALGARY, Sept. 8 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that that it has started patient enrolment in a Phase 2 clinical trial using intravenous administration of REOLYSIN(R) in combination with paclitaxel and carboplatin in patients with advanced head and neck cancers. The Principal Investigator is Dr. Monica Mita of the Cancer Therapy & Research Center (CTRC) at The University of Texas Health Science Center at San Antonio.

"We are extremely pleased to open the second disease-directed study with REOLYSIN(R)," said Dr. Mita. "This study represents a promising option for patients with head and neck tumors refractory to standard chemotherapy and we are happy to have the opportunity to offer this option to our patients."

This trial is a 14-patient, single arm, open-label, dose-targeted, non-randomized trial of REOLYSIN(R) given intravenously in combination with a standard dosage of paclitaxel and carboplatin.

Eligible patients include those with advanced or metastatic head and neck cancers that are refractory to standard therapy or for which no curative standard therapy exists. The primary objective of the Phase 2 trial is to measure tumour responses and duration of response, and to describe any evidence of antitumour activity. The secondary objective is to determine the safety and tolerability of REOLYSIN(R) when administered in combination with paclitaxel and carboplatin to patients with advanced or metastatic head and neck cancers.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I/II and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit '/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. /R E P E A T -- Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours/
2. Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours
3. Oncolytics Biotech Inc. Completes Dose Escalation in Combination REOLYSIN(R)/Docetaxel Trial
4. Oncolytics Biotech Inc. Announces 2008 Second Quarter Results
5. Oncolytics Biotech Inc. Treats 200th Cancer Patient in Clinical Studies with REOLYSIN(R)
6. Oncolytics Biotech Inc. Announces U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
7. Oncolytics Biotech Inc. to Present at BIO 2008 International Convention
8. Oncolytics Biotech Inc. Announces Start of Enrolment in Phase 1/2 Ovarian Cancer Clinical Trial with REOLYSIN(R)
9. Oncolytics Biotech Inc. Starts Patient Enrolment in U.K. Phase II Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
10. Oncolytics Biotech Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at ASCO Annual Meeting
11. Oncolytics Biotech Inc. Collaborators to Present Reovirus Research at ASGT Meeting

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)...2 S*BIO Pte Ltd today announced da... SB1518, at The American Society of Hematology 51s..., Data will be presented on the clinical results...detailing its safety, tolerability and pharmacokin...s ranging from 100 to 600 mg. These doses were adm...
(Date:12/2/2009)... Dec. 2 /PRNewswire-Asia/ -- Simcere Pharmaceutica...), a leading pharmaceutical company,specializing i... branded,generic and proprietary pharmaceuticals i...e been included in China,s National Drug Reimburse...nistry of Human Resources and Social,Security on N...
(Date:12/2/2009)...2 /PRNewswire-Asia/ -- The world is going through,...certainty is part of many,businesses and industrie...relatively immune to the economic downturn, becaus...ng the midst of the difficult times this year, the...rated an R&D center in Shanghai, the largest o...
(Date:12/2/2009)... According to the National Institu...s diagnosed with diabetes already have some stage ...mage to the retina caused by leaky blood vessels, ...tes and is one of the most feared diabetic complic... who,ve had diabetes for 10 years or more will exp...
Breaking Biology Technology:S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5Simcere Announces 105 Drugs Included in China's National Drug Reimbursement List 2Simcere Announces 105 Drugs Included in China's National Drug Reimbursement List 3Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 2Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 3Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 2Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 3Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 4
...ecuring venture investments, commercializing techn...ng innovative companies in Wisconsin will not read...into federal government dollars. , ,This is the p...reated by a collaboration between the Wisconsin lo...e national economic development agency GSP Consul...
... Building the Merge Healthcare of tomorrow, as c...will mean offshoring 150 jobs to a "more cost effe...8 percent of the financially troubled medical imag...tes, Canada, and Japan to regain the competitive e...ion initiative euphemistically labeled rightsizing...
...a natural biological response to the phrase securi...opaque film over the outside of the cornea wall, c... avoid this, I will do my best to stick to the ess... from comprehensive. So if your company is raising...ho is familiar with securities laws early so that ...
Other Biology Technology:New firm to help companies land federal dollars 2Merge offshoring jobs to "more cost-effective" workforce 2Merge offshoring jobs to "more cost-effective" workforce 3Securities compliance is part of raising capital 2Securities compliance is part of raising capital 3Securities compliance is part of raising capital 4
(Date:12/2/2009)...ur muscles can twitch, before the thought telling ...ate of sortscalled an ion channelmust open in the ... chemical signals that spur the cell to action. Ne... and Technology (NIST) has allowed scientists to o...r the first time, potentially offering insights fo...
(Date:12/2/2009)... the University of Salamanca and another from Yale...ors affects the behaviour of Acanthodactylus beer... in the Near East. According to the study, these r...ent prey if they are under pressure from predators...esult, but until now there had been very few exper...
(Date:12/1/2009)...ants have two different feeding strategies. A lar...aning that they are generalist predators feeding o...ns. Some, however, are "herbivorous". This is no...lk of their diets consist of plant-derived matter....d by plants to attract ants, called extra-floral n...
Breaking Biology News(10 mins):Nervy research: Researchers take initial look at ion channels in a model system 2Lizards change their diet to avoid predators 2Bacterial gut symbionts are tightly linked with the evolution of herbivory in ants 2NIH researchers identify key factor that stimulates brain cancer cells to spread 54768 1NIH researchers identify key factor that stimulates brain cancer cells to spread 54768 2NIH researchers identify key factor that stimulates brain cancer cells to spread 54768 3 26quot 3BMed Records to Go 26quot 3B Stores Document and Image Files of Medical Facilities for Emergency Viewing 54765 1 26quot 3BMed Records to Go 26quot 3B Stores Document and Image Files of Medical Facilities for Emergency Viewing 54765 2 26quot 3BMed Records to Go 26quot 3B Stores Document and Image Files of Medical Facilities for Emergency Viewing 54765 3Medicare Picks N J to Test Innovative Incentive System 54762 1Medicare Picks N J to Test Innovative Incentive System 54762 2Medicare Picks N J to Test Innovative Incentive System 54762 3Medicare Picks N J to Test Innovative Incentive System 54762 4
...ression, researchers have found that variation in ...e with age. The findings, which impact our underst...ated changes, are reported in the May 23rd issue o...t the Max Planck Institute for Evolutionary Anthro...g-standing observation concerning the physiologica...
...e autistic brain has fewer neurons in an area rela... new study published in the July 19 issue of The ...quantitative evidence linking autism to an abnorma...us—a major emotion-processing area with connection...nitive functions. , "These new findings, based...
...n and Australian researchers announced June 20, 20...he way people respond to HIV. , Through the new co...vestigators who once competed to unravel the myste...alled cohorts, they have studied. , Support for t...DS Vaccine Immunology (CHAVI), established at Duke...
Other Biology News:Gene expression becomes heterogeneous with age in humans and rats 2Autistic brain has fewer neurons for processing emotion 2CHAVI announces international search for genes affecting HIV response 2CHAVI announces international search for genes affecting HIV response 3
Illumina Custom Data Analysis Report from Asuragen, Inc.
DKW/Juglans Basal Salt Mixture from Sigma-Aldrich
BD Falcon Roller Bottle, smooth surface from BD Biosciences - Discovery Labware
...convenient method for the rapid, thorough lysis of...ith S. cerevisiae and C. albicans but can be used ...t lytic enzyme digestion. The Zymolyase digestion ...ast cells that are ideal for both protein and DNA ...
Biology Products: